SARS-CoV-2 pathogenesis
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
caused a devastating pandemic. Although most people infected with SARS-CoV-2 develop …
caused a devastating pandemic. Although most people infected with SARS-CoV-2 develop …
Mild or moderate Covid-19
Key Clinical Points Mild or Moderate Covid-19 Covid-19 has a range of clinical
manifestations, including cough, fever, myalgias, gastrointestinal symptoms, and anosmia …
manifestations, including cough, fever, myalgias, gastrointestinal symptoms, and anosmia …
[HTML][HTML] Features, evaluation, and treatment of coronavirus (COVID-19)
M Cascella - 2020 - ncbi.nlm.nih.gov
Objectives: Screen individuals based on exposure and symptom criteria to identify potential
COVID-19 cases. Identify the clinical features and radiological findings expected in patients …
COVID-19 cases. Identify the clinical features and radiological findings expected in patients …
[HTML][HTML] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - Lancet (London, England), 2021 - ncbi.nlm.nih.gov
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
Repurposed antiviral drugs for Covid-19—interim WHO solidarity trial results
WHO Solidarity Trial Consortium - New England journal of …, 2021 - Mass Medical Soc
Abstract Background World Health Organization expert groups recommended mortality trials
of four repurposed antiviral drugs—remdesivir, hydroxychloroquine, lopinavir, and interferon …
of four repurposed antiviral drugs—remdesivir, hydroxychloroquine, lopinavir, and interferon …
[HTML][HTML] Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19)
A Aleem, AS Ab, AK Slenker - 2021 - europepmc.org
Objectives: Describe the clinical manifestations, including extrapulmonary manifestations of
COVID-19. Outline the latest treatments available in the management of COVID-19 …
COVID-19. Outline the latest treatments available in the management of COVID-19 …
Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Background Lopinavir–ritonavir has been proposed as a treatment for COVID-19 on the
basis of in vitro activity, preclinical studies, and observational studies. Here, we report the …
basis of in vitro activity, preclinical studies, and observational studies. Here, we report the …
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
Drug treatments for covid-19: living systematic review and network meta-analysis
Objective To compare the effects of treatments for coronavirus disease 2019 (covid-19).
Design Living systematic review and network meta-analysis. Data sources WHO covid-19 …
Design Living systematic review and network meta-analysis. Data sources WHO covid-19 …
Early high-titer plasma therapy to prevent severe Covid-19 in older adults
R Libster, G Pérez Marc, D Wappner… - … England Journal of …, 2021 - Mass Medical Soc
Background Therapies to interrupt the progression of early coronavirus disease 2019 (Covid-
19) remain elusive. Among them, convalescent plasma administered to hospitalized patients …
19) remain elusive. Among them, convalescent plasma administered to hospitalized patients …